Clinical Evidence Behind Semaglutide for Weight Management The STEP trials, which enrolled over 4,500 participants with obesity, demonstrated that semaglutide produces significant weight loss compared to lifestyle changes alone
If a mix-up occurs, contact your healthcare provider immediately
Some users may experience nausea, diarrhoea, constipation, stomach discomfort, or reduced appetite, particularly when first starting treatment
Yes, but only in accordance with FDA guidance when approved products are in shortage
The weight loss was achieved gradually and sustained throughout the study period, with participants maintaining significant reductions even at the 48-week endpoint